New concepts in antimalarial use and mode of action in dermatology
Identifieur interne : 001B27 ( Main/Exploration ); précédent : 001B26; suivant : 001B28New concepts in antimalarial use and mode of action in dermatology
Auteurs : Sunil Kalia ; Jan P. DutzSource :
- Dermatologic Therapy [ 1396-0296 ] ; 2007-07.
English descriptors
- Teeft :
- Acad, Acad dermatol, Acute exacerbation, American academy, Annulare, Antimalarial, Antimalarial agents, Antimalarial drugs, Antimalarial therapy, Arch dermatol, Arthritis, Arthritis rheum, Chloroquine, Chloroquine therapy, Clin, Clin dermatol, Congenital abnormalities, Corneal deposits, Corticosteroid, Cutanea, Cutaneous, Cutaneous lesions, Cutaneous lupus erythematosus, Cutaneous manifestations, Cytokine, Dendritic cells, Dermatol, Dermatology, Dermatomyositis, Dutz, Erythematosus, Generalized granuloma annulare, Granuloma, Granuloma annulare, Hydroxychloroquine, Hydroxychloroquine retinopathy, Hydroxychloroquine sulfate, Hydroxychloroquine treatment, Immunol, Kalia, Kalia dutz, Lean body weight, Lesion, Lichen, Lichen planus, Lupus, Lupus erythematosus, Lupus panniculitis, Lupus patients, Lupus pregnancy, Lymphocyte, Lysosomal, Lysosomotropic, Lysosomotropic agents, Open trial, Ophthalmol, Oral administration, Oral chloroquine, Oral lichen planus, Panniculitis, Placebo, Planus, Polymorphous light eruption, Porphyria, Porphyria cutanea tarda, Psoriasis, Psoriatic arthritis, Quinacrine, Quinacrine therapy, Quinine, Receptor, Retinal toxicity, Retinopathy, Rheum, Rheumatoid, Rheumatoid arthritis, Rheumatol, Sarcoidosis, Semin arthritis rheum, Side effects, Skin disease, Solar urticaria, Soluble antigens, Systemic, Systemic corticosteroids, Systemic lupus erythematosus, Tarda, Toxicity.
Abstract
ABSTRACT: Although chloroquine, hydroxychloroquine and quinacrine were originally developed for the treatment of malaria, these medications have been used to treat skin disease for over 50 years. Recent clinical data have confirmed the usefulness of these medications for the treatment of lupus erythematosus. Current research has further enhanced our understanding of the pharmacologic mechanisms of action of these drugs involving inhibition of endosomal toll‐like receptor (TLR) signaling limiting B cell and dendritic cell activation. With this understanding, the use of these medications in dermatology is broadening. This article highlights the different antimalarials used within dermatology through their pharmacologic properties and mechanism of action, as well as indicating their clinical uses. In addition, contraindications, adverse effects, and possible drug interactions of antimalarials are reviewed.
Url:
DOI: 10.1111/j.1529-8019.2007.00131.x
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000005
- to stream Istex, to step Curation: 000005
- to stream Istex, to step Checkpoint: 000A10
- to stream Main, to step Merge: 001B38
- to stream Main, to step Curation: 001B27
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">New concepts in antimalarial use and mode of action in dermatology</title><author><name sortKey="Kalia, Sunil" sort="Kalia, Sunil" uniqKey="Kalia S" first="Sunil" last="Kalia">Sunil Kalia</name></author><author><name sortKey="Dutz, Jan P" sort="Dutz, Jan P" uniqKey="Dutz J" first="Jan P" last="Dutz">Jan P. Dutz</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:60140524A4951B5428426260EE4BE2CDE3B0A480</idno><date when="2007" year="2007">2007</date><idno type="doi">10.1111/j.1529-8019.2007.00131.x</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-WPWHPMDF-F/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000005</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000005</idno><idno type="wicri:Area/Istex/Curation">000005</idno><idno type="wicri:Area/Istex/Checkpoint">000A10</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000A10</idno><idno type="wicri:doubleKey">1396-0296:2007:Kalia S:new:concepts:in</idno><idno type="wicri:Area/Main/Merge">001B38</idno><idno type="wicri:Area/Main/Curation">001B27</idno><idno type="wicri:Area/Main/Exploration">001B27</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">New concepts in antimalarial use and mode of action in dermatology</title><author><name sortKey="Kalia, Sunil" sort="Kalia, Sunil" uniqKey="Kalia S" first="Sunil" last="Kalia">Sunil Kalia</name><affiliation><wicri:noCountry code="subField">BC</wicri:noCountry></affiliation></author><author><name sortKey="Dutz, Jan P" sort="Dutz, Jan P" uniqKey="Dutz J" first="Jan P" last="Dutz">Jan P. Dutz</name><affiliation><wicri:noCountry code="subField">BC</wicri:noCountry></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Dermatologic Therapy</title><title level="j" type="alt">DERMATOLOGIC THERAPY</title><idno type="ISSN">1396-0296</idno><idno type="eISSN">1529-8019</idno><imprint><biblScope unit="vol">20</biblScope><biblScope unit="issue">4</biblScope><biblScope unit="page" from="160">160</biblScope><biblScope unit="page" to="174">174</biblScope><biblScope unit="page-count">15</biblScope><publisher>Blackwell Publishing Inc</publisher><pubPlace>Malden, USA</pubPlace><date type="published" when="2007-07">2007-07</date></imprint><idno type="ISSN">1396-0296</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1396-0296</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Acad</term><term>Acad dermatol</term><term>Acute exacerbation</term><term>American academy</term><term>Annulare</term><term>Antimalarial</term><term>Antimalarial agents</term><term>Antimalarial drugs</term><term>Antimalarial therapy</term><term>Arch dermatol</term><term>Arthritis</term><term>Arthritis rheum</term><term>Chloroquine</term><term>Chloroquine therapy</term><term>Clin</term><term>Clin dermatol</term><term>Congenital abnormalities</term><term>Corneal deposits</term><term>Corticosteroid</term><term>Cutanea</term><term>Cutaneous</term><term>Cutaneous lesions</term><term>Cutaneous lupus erythematosus</term><term>Cutaneous manifestations</term><term>Cytokine</term><term>Dendritic cells</term><term>Dermatol</term><term>Dermatology</term><term>Dermatomyositis</term><term>Dutz</term><term>Erythematosus</term><term>Generalized granuloma annulare</term><term>Granuloma</term><term>Granuloma annulare</term><term>Hydroxychloroquine</term><term>Hydroxychloroquine retinopathy</term><term>Hydroxychloroquine sulfate</term><term>Hydroxychloroquine treatment</term><term>Immunol</term><term>Kalia</term><term>Kalia dutz</term><term>Lean body weight</term><term>Lesion</term><term>Lichen</term><term>Lichen planus</term><term>Lupus</term><term>Lupus erythematosus</term><term>Lupus panniculitis</term><term>Lupus patients</term><term>Lupus pregnancy</term><term>Lymphocyte</term><term>Lysosomal</term><term>Lysosomotropic</term><term>Lysosomotropic agents</term><term>Open trial</term><term>Ophthalmol</term><term>Oral administration</term><term>Oral chloroquine</term><term>Oral lichen planus</term><term>Panniculitis</term><term>Placebo</term><term>Planus</term><term>Polymorphous light eruption</term><term>Porphyria</term><term>Porphyria cutanea tarda</term><term>Psoriasis</term><term>Psoriatic arthritis</term><term>Quinacrine</term><term>Quinacrine therapy</term><term>Quinine</term><term>Receptor</term><term>Retinal toxicity</term><term>Retinopathy</term><term>Rheum</term><term>Rheumatoid</term><term>Rheumatoid arthritis</term><term>Rheumatol</term><term>Sarcoidosis</term><term>Semin arthritis rheum</term><term>Side effects</term><term>Skin disease</term><term>Solar urticaria</term><term>Soluble antigens</term><term>Systemic</term><term>Systemic corticosteroids</term><term>Systemic lupus erythematosus</term><term>Tarda</term><term>Toxicity</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">ABSTRACT: Although chloroquine, hydroxychloroquine and quinacrine were originally developed for the treatment of malaria, these medications have been used to treat skin disease for over 50 years. Recent clinical data have confirmed the usefulness of these medications for the treatment of lupus erythematosus. Current research has further enhanced our understanding of the pharmacologic mechanisms of action of these drugs involving inhibition of endosomal toll‐like receptor (TLR) signaling limiting B cell and dendritic cell activation. With this understanding, the use of these medications in dermatology is broadening. This article highlights the different antimalarials used within dermatology through their pharmacologic properties and mechanism of action, as well as indicating their clinical uses. In addition, contraindications, adverse effects, and possible drug interactions of antimalarials are reviewed.</div></front></TEI><affiliations><list></list><tree><noCountry><name sortKey="Dutz, Jan P" sort="Dutz, Jan P" uniqKey="Dutz J" first="Jan P" last="Dutz">Jan P. Dutz</name><name sortKey="Kalia, Sunil" sort="Kalia, Sunil" uniqKey="Kalia S" first="Sunil" last="Kalia">Sunil Kalia</name></noCountry></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001B27 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001B27 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:60140524A4951B5428426260EE4BE2CDE3B0A480
|texte= New concepts in antimalarial use and mode of action in dermatology
}}
| This area was generated with Dilib version V0.6.33. |  |